Back to top
more

ResMed (RMD)

(Real Time Quote from BATS)

$273.26 USD

273.26
223,100

+0.66 (0.24%)

Updated Sep 17, 2025 01:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia

by Zacks Equity Research

BioSig Technologies (BSGM) signs agreement with Mayo Foundation for improving arrhythmia treatment along with covering therapies for autonomic nervous system disease.

Zacks Equity Research

Here's Why You Should Invest in ResMed (RMD) Stock Right Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) on its stellar performance.

Zacks Equity Research

Cooper Companies (COO) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Better-than-expected performance at CVI and CSI, and higher revenues are likely to have aided Cooper Companies (COO) in Q4 earnings.

Zacks Equity Research

Intuitive (ISRG) at a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Intuitive Surgical (ISRG) has been gaining from a series of positive developments of late.

Mark Vickery headshot

Top Stock Reports for Walmart, Nike & Citigroup

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Nike, Inc. (NKE) and Citigroup Inc. (C).

Zacks Equity Research

Medtronic Displays All-Business-Line Growth Despite Cost Woes

by Zacks Equity Research

Medtronic's (MDT) Diabetes group is expanding internationally on the strong rollout of its MiniMed 670G in untapped markets.

Zacks Equity Research

Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark

by Zacks Equity Research

Hologic (HOLX) wins the CE Mark for long-term use of LOCalizer RFID tag, providing more flexibility to breast-conserving surgery.

Zacks Equity Research

QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus

by Zacks Equity Research

QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.

Zacks Equity Research

Neogen's (NEOG) Food Safety Test Receives AOAC Clearance

by Zacks Equity Research

Neogen's (NEOG) Reveal 3-D safety test for checking peanut contamination in food items gets approval from the AOAC.

Zacks Equity Research

Bio-Rad's Blood Typing Market Growth Strong on New Products

by Zacks Equity Research

Bio-Rad's (BIO) new product acceptance in the United States is a positive with the recent 510(k) clearance of the IH-Reader 24.

Zacks Equity Research

Amedisys (AMED) to Broaden Hospice Base With Asana Purchase

by Zacks Equity Research

Asana's acquisition to be the third hospice care buyout of Amedisys (AMED) in 2019.

Zacks Equity Research

Medtronic Gets FDA Nod for IN.PACT AV for ESRD Patients

by Zacks Equity Research

Medtronic (MDT) receives FDA clearance for IN.PACT AV for the treatment of arteriovenous failures in patients undergoing hemodialysis.

Zacks Equity Research

Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now

by Zacks Equity Research

Investor confidence in Tandem Diabetes (TNDM) stock is at a high, thanks to solid prospects.

Zacks Equity Research

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.

Zacks Equity Research

NuVasive Gets FDA Nod for CoRoent Small Interlock System

by Zacks Equity Research

NuVasive (NUVA) receives the FDA clearance for expanded use of its Interlock system for minimally disruptive spine surgery at multiple levels.

Zacks Equity Research

Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds

by Zacks Equity Research

Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.

Zacks Equity Research

Henry Schein to Showcase New Dental Offerings at GNYDM

by Zacks Equity Research

Henry Schein's (HSIC) suite of solutions, education, & social media activity featuring dental industry leaders to enable dental professionals to explore new options revolutionizing digital dentistry.

Zacks Equity Research

Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan

by Zacks Equity Research

The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.

Zacks Equity Research

Dexcom (DXCM) Hits a 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Dexcom (DXCM) gains from several positive developments.

Zacks Equity Research

Myriad Genetics' Test Added in Disease Activity Measure List

by Zacks Equity Research

Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.

Zacks Equity Research

Hologic (HOLX) Set to Divest Medical Aesthetics Business

by Zacks Equity Research

Hologic (HOLX) to sell off its medical aesthetics business to focus on other core segments.

Zacks Equity Research

Zacks.com featured highlights include: Nexstar Broadcasting Group, ResMed, Lam Research, Qorvo and Northrop Grumman

by Zacks Equity Research

Zacks.com featured highlights include: Nexstar Broadcasting Group, ResMed, Lam Research, Qorvo and Northrop Grumman

Zacks Equity Research

NUVA or RMD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NUVA vs. RMD: Which Stock Is the Better Value Option?

Zacks Equity Research

What's in the Cards for Veeva Systems (VEEV) in Q3 Earnings?

by Zacks Equity Research

Robust product portfolio and higher revenues are likely to have benefited Veeva Systems (VEEV) in third-quarter fiscal 2020 earnings.

Zacks Equity Research

Haemonetics Launches TEG 6s PlateletMapping Assay Cartridge

by Zacks Equity Research

The global commercial availability of the cartridge is likely to bolster Haemonetics' (HAE) TEG portfolio.